MediWound to Report Third Quarter 2026 Financial Results

MediWound (Nasdaq: MDWD) will release its third-quarter 2026 financial results on November 12, 2026, covering the quarter ended September 30.

Rhea-AI Summary

MediWound (Nasdaq: MDWD) will release its third-quarter 2026 financial results on November 12, 2026, covering the quarter ended September 30. Management will then host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. A webcast replay will be available in the Investors section of the company’s website.

Key Figures

Scheduled results release: November 12, 2026

Scheduled results release

November 12, 2026

Third-quarter 2026 financial results

Key Terms

eschar, debridement

2 terms

eschar medical

"enzymatic removal of eschar in thermal burns"

A dry, dark scab of dead tissue that forms over a wound or ulcer when skin cells and blood supply have been damaged; it’s the crusty layer doctors inspect to judge healing or infection. For investors, eschar matters in healthcare contexts because its presence, size, or changes can signal how well a treatment, device or wound-care product is working, or indicate complications that may affect clinical outcomes and regulatory reviews.

debridement medical

"therapy for the debridement of chronic wounds"

Debridement is the medical removal of dead, infected, or damaged tissue and foreign material from a wound to promote healing, similar to pruning dead branches so new growth can flourish. For investors, it matters because how debridement is performed — by drugs, devices, dressings, or procedures — affects clinical outcomes, product demand, reimbursement decisions, regulatory approval pathways, and the financial prospects of companies offering those solutions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MediWound to Report Third Quarter 2026 Financial Results

Conference Call and Webcast Scheduled for Thursday, November 12^th at 8:30 a.m. Eastern Time

YAVNE, Israel, October 29, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2026, on Thursday, November 12, 2026.

Following the release, Mediwound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

Conference Call & Webcast Details
Toll-Free:                1-844-676-8833
Israel:                     03-374-1008
International:          1-412-634-6869
Webcast:                Click HERE

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.  An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics for tissue repair. The company’s FDA-approved biologic, NexoBrid^®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, the European Union, Japan, and additional international markets. MediWound’s late-stage development candidate, EscharEx^®, is an investigational therapy for the debridement of chronic wounds, with the potential to become a new standard of care in wound management.

For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter).

MediWound Contacts:                                                        

Hani Luxenburg                                                 Daniel Ferry
Chief Financial Officer                                       Managing Director
MediWound Ltd.                                                LifeSci Advisors, LLC
ir@mediwound.com                                          daniel@lifesciadvisors.com